{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"SD"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"PD"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Computed tomography (CT) scans were performed at screening, and week 10. Response was assessed using RECIST version 1.0 (Therasse P et al. J Natl Cancer Inst 92:205-216). Per RECIST, target lesions are categorized as follows: complete response (CR): disappearance of all target lesions (no evaluable disease); partial response (PR): ≥ 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD): ≥ 20% increase in the sum of the longest diameter of target lesions; stable disease (SD): small changes that do not meet above criteria.","groups":[{"description":"Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.","id":"OG000","title":"Ipilimumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All subjects who entered the study.","reportingStatus":"POSTED","timeFrame":"up to 10 weeks","title":"Number of Subjects With Best Tumor Response as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST).","type":"PRIMARY","unitOfMeasure":"Participants"}